Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

The 1998, 1999 Patterns of Care Study for Breast Irradiation after Mastectomy in Korea

1998, 1999년도 우리나라에서 시행된 근치적 유방 전절제술 후 방사선치료 현황 조사

  • Published : 2007.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

[ $\underline{Purpose}$ ]: To determine the patterns of evaluation and treatment in patients with breast cancer after mastectomy and treated with radiotherapy. A nationwide study was performed with the goal of improving radiotherapy treatment. $\underline{Materials\;and\;Methods}$: A web- based database system for the Korean Patterns of Care Study (PCS) for 6 common cancers was developed. Randomly selected records of 286 eligible patients treated between 1998 and 1999 from 17 hospitals were reviewed. $\underline{Results}$: The ages of the study patients ranged from 20 to 80 years (median age 44 years). The pathologic T stage by the AJCC was T1 in 9.7% of the cases, T2 in 59.2% of the cases, T3 in 25.6% of the cases, and T4 in 5.3% of the cases. For analysis of nodal involvement, N0 was 7.3%, N1 was 14%, N2 was 38.8%, and N3 was 38.5% of the cases. The AJCC stage was stage I in 0.7% of the cases, stage IIa in 3.8% of the cases, stage IIb in 9.8% of the cases, stage IIIa in 43% of the cases, stage IIIb in 2.8% of the cases, and IIIc in 38.5% of the cases. There were various sequences of chemotherapy and radiotherapy after mastectomy. Mastectomy and chemotherapy followed by radiotherapy was the most commonly performed sequence in 47% of the cases. Mastectomy, chemotherapy, and radiotherapy followed by additional chemotherapy was performed in 35% of the cases, and neoadjuvant chemoradiotherapy was performed in 12.5% of the cases. The radiotherapy volume was chest wall only in 5.6% of the cases. The volume was chest wall and supraclavicular fossa (SCL) in 20.3% of the cases; chest wall, SCL and internal mammary lymph node (IMN) in 27.6% of the cases; chest wall, SCL and posterior axillary lymph node in 25.9% of the cases; chest wall, SCL, IMN, and posterior axillary lymph node in 19.9% of the cases. Two patients received IMN only. The method of chest wall irradiation was tangential field in 57.3% of the cases and electron beam in 42% of the cases. A bolus for the chest wall was used in 54.8% of the tangential field cases and 52.5% of the electron beam cases. The radiation dose to the chest wall was $45{\sim}59.4\;Gy$ (median 50.4 Gy), to the SCL was $45{\sim}59.4\;Gy$ (median 50.4 Gy), and to the PAB was $4.8{\sim}38.8\;Gy$, (median 9 Gy) $\underline{Conclusion}$: Different and various treatment methods were used for radiotherapy of the breast cancer patients after mastectomy in each hospital. Most of treatment methods varied in the irradiation of the chest wall. A separate analysis for the details of radiotherapy planning also needs to be followed and the outcome of treatment is needed in order to evaluate the different processes.

목 적: 유방암에 대한 방사선치료의 적정성과 안전성을 보장하고 궁극적으로 치료효과를 향상시키기 위한 방사선 치료 기술 표준화를 위하여 우리나라 전국 병원을 대상으로 하는 치료형태 조사연구(patterns of care study, PCS)를 계획하였다. 그 두 번째 단계로 근치적 유방 전절제술 후 시행한 방사선치료 방법에 대하여 조사하고 분석하였다. 대상 및 방법: 조사하고자 하는 입력 문항을 개발하였고 동시에 인터넷을 통하여 조사자가 직접 입력할 수 있도록 Web 기반 입력 프로그램(www.pcs.re.kr)을 개발하였다. 대상 환자들은 1998년도에 근치적 유방 전절제술 후 방사선치료를 받은 환자로 전수 조사를 하지 않고 임의 추출하여 조사하였다. 입력 문항은 149개로 병력과 이학적 소견, 수술 소견과 병리소견, 항암화학요법, 호르몬요법, 방사선치료계획, 방사선치료, 치료 중 부작용, 치료 효과, 합병증 등 9군으로 나누어져 있다. 17개 병원에서 입력된 286명의 데이터를 분석하였다. 결 과: 연령은 $20{\sim}81$세(중앙값 44세)였다. 환자의 병기는 AJCC (American Joint Committee on Cancer) 6판에 따라 분류하였으며 T1: 9.7%, T2: 59.2%, T3: 25.6%, T4: 5.2%이었으며 T0가 1예 있었다. 액와림프절 곽청술에서 떼어낸 림프절이 10개 미만인 환자가 10.5%, 10개 이상인 환자가 86.7%이었으며 7.3% 환자에서 림프절 전이가 없었고, 림프절 전이가 3개 이하인 경우가 14%, $4{\sim}9$개가 38.8%, 10개 이상 전이된 경우가 38.5%였다. 따라서 병기 I기: 0.7%, IIa기: 3.8%, IIb기: 9.8%, IIIa기: 43.0%, IIIb기: 2.8%, IIIc기: 38.5%이었다. 방사선치료가 시행된 시기에 따라서는 수술 후에 항암약물치료를 마치고 방사선치료를 한 경우가 47.9%로 가장 많았고, 수술 후 약물치료를 시행하고 방사선치료를 시행한 후에 다시 약물치료를 시행한 경우가 35.0%로 그 다음으로 많았다. 수술 전 약물치료를 시행하고 그 후에 방사선치료를 시행한 경우도 12.5%였다. 방사선치료 범위는 전체의 5.6%가 흉벽만 치료받았고 20.3%는 흉벽과 쇄골상 림프절을, 27.6%는 흉벽과 쇄골상 림프절과 내유방림프절을, 25.9%에서는 흉벽과 쇄골상 림프절을 치료하면서 액와 후방조사를, 19.9%에서는 흉벽과 쇄골상 림프절과 내유방림프절을 치료하면서 액와 후방조사를 시행하였다. 2예(0.7%)에서는 내유방림프절만 치료하였다. 흉벽의 방사선치료 방법에 있어서는 57.3%에서 양쪽 접선조사를 사용하였고, 42%에서는 전자선으로 치료하였다. 양쪽 접선조사를 시행한 경우에는 54.8%에서 조직보상체를 사용하였고, 전자선으로 치료한 경우는 52.5%에서 사용하였으며 흉벽에 조사된 방사선량은 91.3%에서 $45{\sim}50.4\;Gy$이었으며, 5.9%에서 그 이상이 2.8%에서 그 미만이 조사되었다. 쇄골상 림프절에 조사된 방사선량은 89.5%에서 $45{\sim}50.4\;Gy$이었으며, 2.4%에서 그 이상이 8%에서 그 미만이 조사되었다. 결 론: 유방 보존술 후 방사선치료와는 달리 근치적 유방 전절제술 후 방사선치료는 다양한 형태로 시행되고 있음을 알 수 있었다. 향후 치료방법에 따른 치료성적을 분석함으로써 적절한 방사선 치료 방법을 제시할 수 있을 것이다.

Keywords

References

  1. The Korean Breast Cancer Society. Nationwide Korean Breast Cancer data of 2002. J Korean Breast Cancer Society 2004;7:72- 83 https://doi.org/10.4048/jkbcs.2004.7.2.72
  2. Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? a metaanalysis. J Clin Oncol 2000;18:1220- 1229 https://doi.org/10.1200/JCO.2000.18.6.1220
  3. Fisher B, Jeong JH, Anderson S, et al. Twenty- five- year follow- up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567- 575 https://doi.org/10.1056/NEJMoa020128
  4. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node- positive premenopausal women with breast cancer. N Engl J Med 1997;337:956- 962 https://doi.org/10.1056/NEJM199710023371402
  5. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high- risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949- 955 https://doi.org/10.1056/NEJM199710023371401
  6. Overgaard M, Jensen MB, Overgaard J, et al. Post-operative radiotherapy in high- risk postmenopausal breastcancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 1999;353:1641- 1648 https://doi.org/10.1016/S0140-6736(98)09201-0
  7. Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989- 990 https://doi.org/10.1016/S0360-3016(99)00096-6
  8. Taylor ME, Haffty BG, Shank BM, et al. Postmastectomy radiotherapy. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000;215(Suppl):1153- 1170
  9. National Institutes of Health Consensus Development Conference Statement. Adjuvant therapy for breast cancer, November 1- 3, 2000. J Natl Cancer Inst Monogr 2001:5- 15
  10. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539- 1569 https://doi.org/10.1200/JCO.2001.19.5.1539
  11. White J, Moughan J, Pierce LJ, et al. Status of postmastectomy radiotherapy in the United States: a patterns of care study. Int J Radiat Oncol Biol Phys 2004;60:77- 85 https://doi.org/10.1016/j.ijrobp.2004.02.035
  12. Kim IH, Chie EK, Oh DH, et al. A web- based 'Patterns of Care Study' system f or clinical radiation oncology in Korea: development, launching, and characteristics. J Korean Soc Ther Radiol Oncol 2003;21:291- 298
  13. Suh CO, Shin HS, Cho JH, et al. The 1998, 1999 patterns of care study for breast irradiation after breast- conserving surgery in Korea. J Korean Soc Ther Radiol Oncol 2004; 22:192- 199
  14. Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002;53:880- 888 https://doi.org/10.1016/S0360-3016(02)02850-X
  15. Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107- 1117 https://doi.org/10.1200/JCO.1988.6.7.1107
  16. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin- based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000;18:2817- 2827 https://doi.org/10.1200/JCO.2000.18.15.2817
  17. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17: 1689- 1700 https://doi.org/10.1200/JCO.1999.17.6.1689
  18. Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001;50:735- 742 https://doi.org/10.1016/S0360-3016(01)01500-0
  19. Buchholz TA, Austin-Seymour MM, Moe RE, et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993;26:23- 35 https://doi.org/10.1016/0360-3016(93)90169-V
  20. Metz JM, Schultz DJ, Fox K, et al. Analysis of outcomes for high- risk breast cancer based on interval from surgery to postmastectomy radiation therapy. Cancer J 2000;6:324- 330
  21. Buchholz TA. Internal mammary lymph nodes: to treat or not to treat. Int J Radiat Oncol Biol Phys 2000;46:801- 803 https://doi.org/10.1016/S0360-3016(99)00482-4